Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.
Saved in:
| Title: | Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. |
|---|---|
| Authors: | Ramos Perez, Jorge M.1 (AUTHOR), Patel, Keyur P.2 (AUTHOR), Loghavi, Sanam2 (AUTHOR), Garcia-Manero, Guillermo1 (AUTHOR), Borthakur, Gautam1 (AUTHOR), Jabbour, Elias1 (AUTHOR), Wierda, William1 (AUTHOR), Pierce, Sherry1 (AUTHOR), Brandt, Mark1 (AUTHOR), Kornblau, Steven1 (AUTHOR), Kadia, Tapan1 (AUTHOR), Daver, Naval1 (AUTHOR), DiNardo, Courtney D.1 (AUTHOR), Jain, Nitin1 (AUTHOR), Yilmaz, Musa1 (AUTHOR), Short, Nicholas1 (AUTHOR), Verstovsek, Srdan1 (AUTHOR), Ferrajoli, Alessandra1 (AUTHOR), Andreeff, Michael1 (AUTHOR), Konopleva, Marina1 (AUTHOR) |
| Source: | Leukemia & Lymphoma. Mar2022, Vol. 63 Issue 3, p672-675. 4p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
